Skip to main content

Advertisement

SpringerLink
Log in

Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over

  • Obesity Treatment (CM Apovian, Section Editor)
  • Published:
Current Obesity Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

One begins to see improvement in glycemic measures and triglycerides with small amounts of weight loss, but with greater levels of weight loss there is even greater improvement. In fact, the relationship between weight loss and glycemia is one that is very close.

Recent Findings

This is fortunate for diabetes prevention; it takes only small amounts of weight loss to prevent progression to type 2 diabetes from impaired glucose tolerance, and after the 10 kg of weight loss, one cannot demonstrate much additional improvement in risk reduction. Modest weight loss (5 to 10%) is also associated with improvement in systolic and diastolic blood pressure and HDL cholesterol. With all these risk factors, more weight loss produces more improvement. Further, for patients with higher BMI levels (>40 kg/m2), the ability to lose the same proportion of weight with lifestyle intervention is equal to that of those with lower BMI levels, and there is equal benefit in terms of risk factor improvement with modest weight loss. For some comorbid conditions, more weight loss is needed—10 to 15%—to translate into clinical improvement. This is true with obstructive sleep apnea and non-alcoholic steatotic hepatitis. There is a graded improvement in improvements in measures of quality of life, depression, mobility, sexual dysfunction, and urinary stress incontinence, whereby improvements are demonstrable with modest weight loss (5–10%) and with further weight loss there are further improvements. For polycystic ovarian syndrome and infertility, modest weight loss (beginning at 2–5%) can bring improvements in menstrual irregularities and fertility. Moderate weight loss (5–10%) has been shown to be associated with reduced health care costs. Reduction in mortality may take more than 10% weight loss, although definitive studies have not been done to demonstrate that weight loss per se is associated with mortality reduction.

Summary

Clinicians in medical weight management should bear in mind that the target should be health improvement rather than a number on the scale. The individual patient’s targeted health goal should be assessed for response rather than a prescribed percentage weight loss.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Williamson DA, Bray GA, Ryan DH. Is 5% weight loss a satisfactory criterion to define clinically significant weight loss? Obesity (Silver Spring). 2015 Dec;23(12):2319–20.

    Article  Google Scholar 

  2. •• Jensen MD, Ryan DH, Donato KA, et al. Guidelines (2013) for managing overweight and obesity in adults. Obesity. 2014;22:S1–S410. These guidelines are based on a systematic evidence review around 5 critical questions (benefits of weight loss, risks of excess body weight, best diet for weight loss, weight loss with comprehensive lifestyle intervention, and role of bariatric surgery)

    Article  Google Scholar 

  3. U.S. Department of Health and Human Services Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for Industry Developing Products for Weight Management. Draft Guidance. 2007. Revision 1. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071612.pdf. Accessed 7 Jan 2017.

  4. Diabetes Prevention Program Research Group. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.

    Article  PubMed Central  Google Scholar 

  5. Tuomilheto J, Lindström J, Eriksson JG, for the Finnish Diabetes Prevention Study Group, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–50.

    Article  Google Scholar 

  6. Hamman RF, Wing RR, Edelstein SL, et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care. 2006;29(9):2102–7.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34:1481–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Unick JL, Beavers D, Jakicic JM, Kitabchi AE, Knowler WC, Wadden TA, Wing RR, The Look AHEAD Research Group. Effectiveness of lifestyle interventions for individuals with severe obesity and type 2 diabetes. Diabetes Care. 2011;34:2152–7.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Foster GD, Borradaile KE, Sanders MH, Millman R, Zammit G, Newman AB, Wadden TA, Kelley D, Wing RR, Pi-Sunyer FX, Reboussin D, Kuna ST, the Sleep AHEAD Research Group of the Look AHEAD Research Group. A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study. Arch Intern Med. 2009;169(17):1619–26.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Kuna ST, Reboussin DM, Borradaile KE, Sanders MH, Millman RP, Zammit G, Newman AB, Wadden TA, Jakicic JM, Wing RR, Pi-Sunyer FX, Foster GD, Sleep AHEAD Research Group. Long-term effect of weight loss on obstructive sleep apnea severity in obese patients with type 2 diabetes. Sleep. 2013;36(5):641–9.

    PubMed  PubMed Central  Google Scholar 

  11. Messier SP, Loeser RF, Miller GD, Morgan TM, Rejeski WJ, Sevick MA, Ettinger WH, Pahor M, Williamson JD. Exercise and dietary weight loss in overweight and obese older adults with knee osteoarthritis. The Arthritis, Diet, and Activity Promotion Trial. Arthritis & Rheumatism. 2004;50(5):1501–10.

    Article  Google Scholar 

  12. Messier SP, Gutekunst DJ, Davis C, DeVita P. Weight loss reduces knee-joint loads in overweight and obese older adults with knee osteoarthritis. Arthritis & Rheumatism. 2004;52(7):2026–32.

    Article  Google Scholar 

  13. Messier SP, Mihalko SL, Legault C, Miller GD, Nicklas BJ, DeVita P, Beavers DP, Hunter DJ, Lyles MF, Eckstein F, Williamson JD, Carr JJ, Guermazi A, Loeser RF. Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial. JAMA. 2013;310(12):1263–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. • Hunter DJ, Beavers DP, Ekstein F, Guermazi A, Loeser RF, Nicklas BJ, Mihalko SL, Miller GD, Lyles M, DeVita P, Legault C, Carr JJ, Williamson JD, Messier SP. The Intensive Diet and Exercise for Arthritis (IDEA) trial: 18-month radiographic and MRI outcomes. Osteoarthr Cartil. 2015;23:1090–8. This paper demonstrates that despite significant weight loss and improvements in symptoms and function, there are no changes in MRI or x-ray changes with knee osteoarthritis

    Article  CAS  PubMed  Google Scholar 

  15. • White DK, Neogi T, Rejeski WJ, Walkup MP, Lewis CE, Nevitt MC, Foy CG, Felson DT, ARG L. Can an intensive diet and exercise program prevent knee pain among overweight adults at high risk? Arthritis Care Res (Hoboken). 2015;67(7):965–71. This paper demonstrates that a lifestyle intervention producing moderate weight loss (5–10%), compared to a control condition, was associated with a reduction in emergence of knee pain over 1 year in persons with obesity and type 2 diabetes. However, over the next 3 years with 50% of the lost weight being regained, there was no difference in emergent rates of knee pain among study groups

    Article  Google Scholar 

  16. Lazo M, Solga S, Horska A, et al., the Fatty Liver Subgroup of the Look AHEAD Research Group. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care. 2010;33(10):2156–63.

  17. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51(1):121–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Kolotkin RL, Crosby RD, Williams GR, Hartley GG, Nicol S. The relationship between health-related quality of life and weight loss. Obes Res. 2001 Sep;9(9):564–71.

    Article  CAS  PubMed  Google Scholar 

  19. Faulconbridge L, Wadden T, Rubin R, the Look AHEAD Research Group, et al. One-year changes in symptoms of depression and weight in overweight/obese individuals with type 2 diabetes in the Look AHEAD study. Obesity. 2012;20(4):783–93.

    Article  PubMed  Google Scholar 

  20. Rejeski WJ, Ip EH, Bertoni AG, et al. Lifestyle change and mobility in obese adults with type 2 diabetes. N Engl J Med. 2012;366:1209–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Phelan S, Kanaya AM, Subak LL, et al. Weight loss prevents urinary incontinence in women with type 2 diabetes: results from the Look AHEAD trial. J Urol. 2012;187:939–44.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Breyer BN, Phelan S, Hogan PE, The Look AHEAD Research Group, et al. Intensive lifestyle intervention reduces urinary incontinence in overweight/obese men with type 2 diabetes: results from the Look AHEAD trial. J Urol 2014

  23. Wing R, Rosen R, Fava J, Bahnson J, et al. Effects of weight loss intervention on erectile function in older men with type 2 diabetes in the Look AHEAD trial. Journal of Sexual Medicine. 2010;7(1 Pt 1):156–65.

    Article  PubMed  Google Scholar 

  24. Wing RR, Bond DS, Gendrano IN, The Sexual Dysfunction Subgroup of the Look AHEAD Research Group, et al. Effect of intensive lifestyle intervention on sexual dysfunction in women with type 2 diabetes: results from an ancillary Look AHEAD study. Diab Care. 2013;36:2937–44.

    Article  Google Scholar 

  25. Kiddy DS, Hamilton-Fairley D, Bush A, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol. 1992;36:105.

    Article  CAS  Google Scholar 

  26. Crosignani PG, Colombo M, Vegetti W, et al. Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum Reprod. 2003;18:1928.

    Article  PubMed  Google Scholar 

  27. Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab. 1999;84:1470.

    CAS  PubMed  Google Scholar 

  28. • Look AHEAD Research Group. Impact of an intensive lifestyle intervention on use and cost of medical services among overweight and obese adults with Type 2 diabetes. Diabetes Care. 2014;37(9):2548–56. This paper shows that modest weight loss (mean 8.7% weight loss at 1 year, with regain of 50% over the next 3 years) was associated with a reduction in costs for hospitalization and in medication costs, but not outpatient medical care costs

    Article  Google Scholar 

  29. Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, Bengtsson C. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741–52.

    Article  PubMed  Google Scholar 

  30. The Look AHEAD Research Group, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, Espeland MA, Evans M, Foreyt JP, Ghazarian S, Gregg EW, Harrison B, Hazuda HP, Hill JO, Horton ES, Hubbard VS, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montez MG, Murillo A, Nathan DM, Patricio J, Peters A, Pi-Sunyer X, Pownall H, Reboussin D, Regensteiner JG, Rickman AD, Ryan DH, Safford M, Wadden TA, Wagenknecht LE, West DS, Williamson DF, Yanovski SZ. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. New Engl J Med. 2013;369(2):145–54.

    Article  PubMed Central  Google Scholar 

  31. • Look AHEAD Research Group, Gregg EW, Jakicic JM, Blackburn G, Bloomquist P, Bray GA, Clark JM, Coday M, Curtis JM, Egan C, Evans M, Foreyt J, Foster G, Hazuda HP, Hill JO, Horton ES, Hubbard VS, Jeffery RW, Johnson KC, Kitabchi AE, Knowler WC, Kriska A, Lang W, Lewis CE, Montez MG, Nathan DM, Neiberg RH, Patricio J, Peters A, Pi-Sunyer X, Pownall H, Redmon B, Regensteiner J, Rejeski J, Ribisl PM, Safford M, Stewart K, Trence D, Wadden TA, Wing RR, Yanovski SZ. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2016;4(11):913–21. For patients who lost 10% or more in the first year of the study, there was a reduction in major cardiovascular events

    Article  Google Scholar 

  32. Messier RP, Gutekunst DJ, Davis C, DeVita P. Arthritis & rheumatism. 2005;52(7):2026–32.

    Article  Google Scholar 

  33. Sikaris KA. The clinical biochemistry of obesity. Clin Biochem Rev. 2004 Aug;25(3):165–81.

    PubMed  PubMed Central  Google Scholar 

  34. Bays H. Central obesity as a clinical marker of adiposopathy; increased visceral adiposity as a surrogate marker for global fat dysfunction. Curr Opin Endocrinol Diabetes Obes. 2014;21(5):345–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. •• Magkos F, Fraterrigo G, Yoshino J, Luecking C, Kirbach K, Kelly SC, de las Fuentes K, Sonbing H, Okunade AL, Patterson BW, Klein S. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab. 2016;23:1–11. This paper measures advanced clinical endpoints and performs measurements at baseline, after 5% weight loss, after 11% weight loss, and after 16% weight loss and compares to a control, stable-weight condition. It provides insight into the mechanisms by which weight reduction produces effects on different tissues

    Article  Google Scholar 

  36. Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion. http://www.cdc.gov/arthritis/resources/spotlights/kneereplacements.htm.

  37. Williamson D, Rejeski J, Lang W, and the Look AHEAD Research Group, et al. Impact of a weight management program on health-related quality of life in overweight adults with type 2 diabetes. Arch Intern Med. 2009;169(2):163–71.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–71.

    Article  CAS  PubMed  Google Scholar 

  39. Boots C, Stephenson MD. Does obesity increase the risk of miscarriage in spontaneous conception: a systematic review. Semin Reprod Med. 2011;29:507.

    Article  PubMed  Google Scholar 

  40. •• Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, Nadolsky K, Pessah-Pollack R, Plodkowski R, reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for Comprehensive Medical Care of Patients with Obesity—Executive Summary. Endocr Pract. 2016;22(7):842–84. New guidelines from the AACE organization emphasize complications-centric, rather than BMI-centric treatment decisions for patients with overweight and obesity

    Article  PubMed  Google Scholar 

  41. http://www.acog.org/About-ACOG/ACOG-Departments/Toolkits-for-Health-Care-Providers/Obesity-Toolkit. Accessed 22 Feb 2017.

Download references

Author information

Authors and Affiliations

  1. Pennington Biomedical Research Center, 6400 Perkins Road, Baton Rouge, LA, 70808, USA

    Donna H. Ryan

  2. Department of Obstetrics and Gynecology, LSU School of Medicine, 1542 Tulane Avenue, New Orleans, LA, USA

    Sarah Ryan Yockey

Authors
  1. Donna H. Ryan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sarah Ryan Yockey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Donna H. Ryan.

Ethics declarations

Conflict of Interest

D.H.R. and S.R.Y. declare they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Obesity Treatment

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ryan, D.H., Yockey, S.R. Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over. Curr Obes Rep 6, 187–194 (2017). https://doi.org/10.1007/s13679-017-0262-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13679-017-0262-y

Keywords

Search

Navigation